wegovy HD. 20.7%. zepbound. 22.5%. not sweating it.
Company: Eli Lilly
Tags: field, strategy, launch
efficacy gap still exists and it matters for the severe patients. NVO will lead with "new dose" everywhere — fine. tirzepatide story hasnt changed oral semaglutide is the thing I'm actually watching. pill with broad formulary coverage is a different fight
12 upvotes · 5 comments